Buesa Grant 2016

Nadia Hindi

Instituto de Biomedicina de Sevilla (IBIS),
Hosp. Univ. Virgen del Rocío, Sevilla

ROLE OF IMMUNOMODULATION AND ITS RELEVANCE AS TERAPEUTIC TARGET IN SOFT TISSUE SARCOMA

AIMS

- Establishment of reliable PD-L1 and FAS detection methods→ standardize the protocol of IHQ
- Testing biomarkers: PD-L1, PD-1 in inflammatory cells, FAS, FASL, CD3, CD4, FoxP3, Calreticulin and TOPO2A
- Analysis of prognostic and predictive role of PD-L1 and FAS in a cohort of metastatic soft-tissue sarcoma

ROLE OF IMMUNOMODULATION AND ITS RELEVANCE AS TERAPEUTIC TARGET IN SOFT TISSUE SARCOMA

METHODS

- Paraffin-embedded tumor block
- Blood: baseline, assessments, progression

- PROTEIN EXPRESSION
  - IHQ: TMA and control (complete sections)
  - FAS and PD-L1 levels among others by Platinum ProcartaPlex® Immunoassays (plasma)

- RNA EXPRESSION (qR-PCR): PD-L1, PC-1, FAS, FASL, FOXP3, CALR, TOPO2A

ROLE OF IMMUNOMODULATION AND ITS RELEVANCE AS TERAPEUTIC TARGET IN SOFT TISSUE SARCOMA



ROLE OF IMMUNOMODULATION AND ITS RELEVANCE AS TERAPEUTIC TARGET IN SOFT TISSUE SARCOMA

- FOLLOW-UP
- Trial opened recruitment in May 2017
- Phase I completed in October 2017
- Phase II on-going (recruitment almost completed in STS cohort)

- Results from Phase I communicated in ASCO 2018

ROLE OF IMMUNOMODULATION AND ITS RELEVANCE AS TERAPEUTIC TARGET IN SOFT TISSUE SARCOMA

- Samples (26th September 2018)
- Tissue:

	n
Baseline tissue	58
Week 13 tissue	30

- Blood:

	n
Baseline blood	56
Week 3 blood	54
Week 13 blood	30
Radiological response/PD	28

ROLE OF IMMUNOMODULATION AND ITS RELEVANCE AS TERAPEUTIC TARGET IN SOFT TISSUE SARCOMA

- TIMELINE
- November: STS cohort close and all samples in IBIS
- December/January: Staining (IHQ) and cytokine analysis
- January 2019→ Abstract ASCO 2019 (correlation of Phase I patients)

HOSPITALES UNIVERSITARIOS
Virgen del Rocío

IBiS
INSTITUTODEBIOMEDICINADESEVILLA

nhindi@mustbesevilla.org

GRACIAS!!